Viewing data from:

CARBIDOPA AND LEVODOPA

ANDA

CARBIDOPA; LEVODOPA | A075091 | MYLAN PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 4 NDCs

Highest NADAC/Unit

$0.1756

per ea

Lowest NADAC/Unit

$0.1185

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378009401CARBIDOPA-LEVO ER 50-200 TAB	$0.1756	EA	Generic	—	2026-06-17
51079092320CARBIDOPA-LEVO ER 50-200 TAB	$0.1756	EA	Generic	—	2026-06-17
00378008801CARBIDOPA-LEVO ER 25-100 TAB	$0.1185	EA	Generic	—	2026-06-17
51079097820CARBIDOPA-LEVO ER 25-100 TAB	$0.1185	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$19.91

Highest Price

$47.24

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
51079-0923-20CARBIDOPA 50MG/LEVODOPA 200MG TAB	$47.24	FSS	Mylan Institutional, Inc.	09/29/2026
51079-0978-20CARBIDOPA AND LEVODOPA 25MG/100MG ER TAB	$19.91	FSS	Mylan Institutional, Inc.	09/29/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 24, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 50MG;200MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Sep 30, 1999

No patent or exclusivity listings for this strength.

#002 — 25MG;100MG

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Apr 21, 2000